

Monkey Pox (MPX) Inventory Management

Prepared by STChealth August 18, 2022

STChealth 411 South 1st Street Phoenix, AZ 85004 480.745.8500 phone 602.598.7712 fax www.STChealth.com



UPDATED: August 17, 2022

Smallpox and Monkeypox Vaccine, Live, Non-Replicating (trade name JYNNEOS) is approved by FDA and recommended for the prevention of smallpox and monkeypox (MPX) disease in adults 18 years of age and older determined to be at high risk for smallpox or MPX infection. JYNNEOS was originally licensed for subcutaneous injection of 2 doses of 0.5 ml given at an interval of 28 days. Throughout 2022 supplies of JYNNEOS are expected to be limited. The number of doses at the standard 0.5 ml volume are insufficient to protect prioritized populations at risk of contracting MPX during the current epidemic.

On August 9, 2022, FDA issued Emergency Use Authorization (EUA) for intradermal injection of doses of 0.1 ml as an alternative to subcutaneous injection for adults 18 years and older, similarly given as a 2-dose series at an interval of 28 days. Subsequent guidance from CDC endorses intradermal vaccination of adults against MPX.

In order to maximize the number of individuals that can benefit from JYNNEOS vaccine during this epidemic, CDC recommends intradermal administration (0.1mL) with exceptions for subcutaneous use noted in current CDC guidance for identified populations.

Contents

Background Information	3
Managing Monkey Pox Inventory	3
Step One – State/Jurisdiction VOMS User	3
Step Two - Provider/VOMS User	4
Decrementing Administered Monkey Pox Vaccines	4
Step 3a – Provider User, Intradermal Administration	4
Step 3b – Provider User, Subcutaneous Administration	5
Decrementing Additional Monkey Pox Doses	5
Step 4a - Provider User, Wasted Doses	6
Step 4b - Provider User, 0.5mL Administered	6



Background Information

The following are helpful tips to know about STC|ONE Inventory Management with MPX:


- 1. STC|ONE uses the Dose Size and not the Volume (CC) to decrement the appropriate dose from the inventory.
- 2. Dose Size is defined on the Vaccine Settings page
- 3. STC|ONE does not have a way to account for a dose size of 1/5th or quintuple/fivefold/five times as would be required with the recent changes for MPX.

Managing Monkey Pox Inventory

The majority of the population will receive the intradermal administration (0.1mL) of the vaccine as such, the following recommendations should be made to effectively manage the MPX inventory with two different volume/dose sizes are available.

Step One - State/Jurisdiction VOMS User

Adjust your Product Settings and Vaccine Settings page to reflect the volume change from 0.5mL to 0.1mL. Product Settings



Vaccine Settings





Step Two - Provider/VOMS User


Adjust your current MPX inventory by 5 times to accurately reflect the change from 0.5mL to 0.1mL. There are two adjustment reasons that can be used; both will achieve the same result.

- 1. Order Received Dose Count Variance Multi-dose Vial
- 2. Correction Correction of Invalid Entry

VOMS 1

Lot Numbers > Search/Add > Select Vaccine & Edit > Add Doses. Enter in the Number of Doses Added and Apply Changes.

Currently have 10 doses available. Add 40 doses. 10 doses x = 50 doses



VOMS 2

Inventory > Search/Add > Select Vaccine & Edit > Adjust. Enter the Actual Doses On Hand and Save. Currently have 10 doses available. Adjusting to 50 doses. 10 doses \times 5 = 50 doses



Decrementing Administered Monkey Pox Vaccines

After making the changes in step one and two to the Facilities inventory, a full dose of MPX is the equivalent of 0.1mL. This will support the majority of patients receiving the intradermal administration. For patients receiving the subcutaneous administration of 0.5mL; the inventory will need to be adjusted to show the 5 doses were decremented.

Step 3a - Provider User, Intradermal Administration

Document the administered MPX Vaccine on the patient record. For patients receiving the MPX intradermally, no changes will need to be made to the inventory.

Manual Entry

- Select the vaccine from your inventory
- Add the Site and Route of administration



- Dose Size will default to "Full Dose"
- Volume can be manually entered but is not tied to the inventory definitions on the Product Settings or Vaccine Settings pages.
- The "Full Dose" will decrement one dose from the inventory



Step 3b - Provider User, Subcutaneous Administration

Document the administered MPX Vaccine on the patient record. For patients receiving the MPX subcutaneously, changes will need to be made to the inventory.

Manual Entry

- Select the vaccine from your inventory
- Add the Site and Route of administration
- Dose Size will default to "Full Dose"
- Volume can be manually entered but is not tied to the inventory definitions on the Product Settings or Vaccine Settings pages.
- The "Full Dose" will decrement one dose from the inventory. Will need to adjust the inventory to ensure the full 5 doses (0.1mL = 1 dose, 0.5mL = 5 doses) are accounted for.



Decrementing Additional Monkey Pox Doses

The MPX inventory will need to be monitored closely. There are two scenarios when the MPX vaccine will need to be reconciled.

- 1. When an entire vial of MPX is not used (5 0.1mL doses), the remaining doses will need to be reconciled as wasted doses.
- 2. When a patient is administered the 0.5mL subcutaneously.



Step 4a - Provider User, Wasted Doses

When there are remaining 0.1mL doses in an open vial that can no longer be used, the Provider reconcile those wasted doses. It is recommended to the Wasted – Drawn up, Not Used reason to capture this. VOMS 1



VOMS 2



Step 4b - Provider User, 0.5mL Administered

Because we have previously adjusted the inventory to reflect the 0.1mL dose, when a patient is administered the 0.5mL dose, additional doses will need to be reconciled to maintain accurate inventory. It is recommended to use the Administered – Administered but not linked to a vaccine reason to capture this. VOMS 1



VOMS 2

